Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Corticosteroids for treating optic neuritis.
Using experimental autoimmune encephalomyelitis as a model to study the effect of prenatal stress on fetal programming.
Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis.
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial.
In vitro Biological Characterization of IFN-β-1a major Glycoforms.
A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone
Materials for stem cell factories of the future.
Vinpocetine inhibits oligodendroglial precursor cell differentiation.
Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.
CD46: The 'multitasker' of complement proteins.
The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis.
Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials.
ATX-MS-1467 - Positive Immunological data in Multiple Sclerosis: Final Phase I/IIa data shows safety and tolerability, plus efficacy
Ampyra (dalfampridine) medication guide
QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients.
Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis
No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.
The NOX1/4 Inhibitor GKT136901 as Selective and Direct Scavenger of Peroxynitrite.
Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group.
Microbial colonization influences early B-lineage development in the gut lamina propria.
Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study.
Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.

Pages